Synonyms: Pabal®
carbetocin is an approved drug (UK (2007))
Compound class:
Peptide
Comment: Carbetocin is an oxytocin analogue. Like oxytocin it acts as an oxytocic, antihemorrhagic and uterotonic drug. Activating this pathway has already been shown to reduce food intake and body weight in both animal models and human clinical studies, and as a result oxytocin (plus analogues and non-peptide mimetics) is being evaluated for anti-obesity potential [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03649477 | Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome | Phase 3 Interventional | Levo Therapeutics, Inc. | ||
NCT01968187 | Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome | Phase 2 Interventional | Ferring Pharmaceuticals |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) |